subjects with do-not-resuscitate (dnr) and/or do-not-intubate (dni) orders or expected to be made dnr/dni in setting of resource limitations or family wishes. not a candidate for dialysis or continuation of care (or full medical support) in setting of resource limitations. subject on continuous vasopressors (at the dose of norepinephrine >20μg/min and/or vasopressin >0.04 units/kg/min) for >48 hours at time of screening. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible. inability to provide informed consent or to comply with test requirements consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment pregnancy or breast feeding subject participating in another study with for an investigational treatment for covid-19. note: subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.

subjects with do-not-resuscitate (dnr) and/or do-not-intubate (dni) orders or expected to be made dnr/dni in setting of resource limitations or family wishes. not a candidate for dialysis or continuation of care (or full medical support) in setting of resource limitations. subject on continuous vasopressors (at the dose of norepinephrine >20μg/min and/or vasopressin >0.04 units/kg/min) for >48 hours at time of screening. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible. inability to provide informed consent or to comply with test requirements consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment pregnancy or breast feeding subject participating in another study with for an investigational treatment for covid-19. note: subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.

1. subjects with do-not-resuscitate (dnr) and/or do-not-intubate (dni) orders or expected to be made dnr/dni in setting of resource limitations or family wishes. 2. not a candidate for dialysis or continuation of care (or full medical support) in setting of resource limitations. 3. subject on continuous vasopressors (at the dose of norepinephrine >20μg/min and/or vasopressin >0.04 units/kg/min) for >48 hours at time of screening. 4. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible. 5. inability to provide informed consent or to comply with test requirements 6. consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment 7. pregnancy or breast feeding 8. subject participating in another study with for an investigational treatment for covid-19. note: subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.

1. subjects with do-not-resuscitate (dnr) and/or do-not-intubate (dni) orders or expected to be made dnr/dni in setting of resource limitations or family wishes. 2. not a candidate for dialysis or continuation of care (or full medical support) in setting of resource limitations. 3. subject on continuous vasopressors (at the dose of norepinephrine >20μg/min and/or vasopressin >0.04 units/kg/min) for >48 hours at time of screening. 4. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible. 5. inability to provide informed consent or to comply with test requirements 6. consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment 7. pregnancy or breast feeding 8. subject participating in another study with for an investigational treatment for covid-19. note: subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.